X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-21 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | S - Sale+OE | $20.29 | -9,000 | 165,820 | -5% | -$182,636 | |||||
| M | 2025-05-21 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.06 | +3,500 | 394,607 | +1% | +$7,200 | |||||
2025-05-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $29.30 | -2,575 | 66,420 | -4% | -$75,436 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $29.75 | -531 | 105,318 | -1% | -$15,796 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $29.75 | -632 | 128,748 | 0% | -$18,800 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $29.75 | -1,877 | 240,783 | -1% | -$55,835 | ||||||
| D | 2025-05-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $29.75 | -2,802 | 649,630 | 0% | -$83,351 | |||||
2025-05-21 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $29.75 | -242 | 51,030 | 0% | -$7,199 | ||||||
2025-05-21 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $29.75 | -936 | 106,018 | -1% | -$27,843 | ||||||
| D | 2025-05-22 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale+OE | $107.52 | -28,000 | 121,152 | -19% | -$3,010,564 | |||||
2025-05-20 | REPL | Replimune Group, Inc. | Astley-Sparke Philip | Dir | S - Sale | $8.06 | -32,279 | 1,405,071 | -2% | -$260,169 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $8.06 | -7,952 | 146,933 | -5% | -$64,093 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $8.05 | -3,287 | 68,284 | -5% | -$26,460 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $8.06 | -25,105 | 343,576 | -7% | -$202,346 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $8.05 | -2,535 | 143,522 | -2% | -$20,407 | ||||||
2025-05-20 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $8.05 | -3,749 | 128,296 | -3% | -$30,179 | ||||||
2025-05-20 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $44.06 | -34,387 | 446,259 | -7% | -$1,515,091 | ||||||
2025-05-21 | EXEL | Exelixis, Inc. | Heyman Tomas J. | Dir | S - Sale | $44.29 | -4,544 | 32,470 | -12% | -$201,254 | ||||||
| M | 2025-05-20 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.02 | +2,300 | 141,666 | +2% | +$4,651 | |||||
2025-05-20 | PRME | Prime Medicine, Inc. | Brudnick Richard | Chief Business Officer | P - Purchase | $1.19 | +20,000 | 20,000 | New | +$23,790 | ||||||
2025-05-21 | PRME | Prime Medicine, Inc. | Lee Ann L. | Chief Technical Officer | P - Purchase | $1.13 | +100,000 | 100,000 | New | +$113,000 | ||||||
2025-05-21 | PRME | Prime Medicine, Inc. | Reine Allan | CEO | P - Purchase | $1.18 | +125,000 | 125,000 | New | +$147,150 | ||||||
| D | 2025-05-21 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.00 | -1,000 | 0 | -100% | -$28,000 | |||||
| D | 2025-05-21 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.59 | -346 | 9,216 | -4% | -$2,624 | |||||
| D | 2025-05-21 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $7.59 | -706 | 46,226 | -2% | -$5,355 | |||||
| M | 2025-05-19 | TCRX | Tscan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $1.20 | +2,588,794 | 14,692,282 | +21% | +$3,106,553 | |||||
| D | 2025-05-20 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $58.43 | -1,500 | 0 | -100% | -$87,645 | |||||
| A | 2025-05-16 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $8.89 | -1,929 | 269,581 | -1% | -$17,149 | |||||
| D | 2025-05-16 | AURA | Aura Biosciences, Inc. | Johnson David Michael | Dir | P - Purchase | $4.90 | +20,000 | 455,839 | +5% | +$98,000 | |||||
| D | 2025-05-16 | AURA | Aura Biosciences, Inc. | Gibney Anthony S | See Remarks | P - Purchase | $4.90 | +50,000 | 56,933 | +721% | +$245,000 | |||||
| D | 2025-05-16 | AURA | Aura Biosciences, Inc. | Gibney Anthony S | See Remarks | S - Sale+OE | $5.15 | -1,519 | 56,933 | -3% | -$7,823 | |||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $2.77 | -1,074 | 221,173 | 0% | -$2,979 | ||||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $2.77 | -585 | 67,681 | -1% | -$1,623 | ||||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $2.77 | -521 | 63,098 | -1% | -$1,445 | ||||||
2025-05-16 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $2.77 | -367 | 59,242 | -1% | -$1,018 | ||||||
2025-05-16 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $6.76 | -2,218 | 37,067 | -6% | -$15,000 | ||||||
2025-05-16 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $6.76 | -3,276 | 70,847 | -4% | -$22,156 | ||||||
2025-05-16 | XFOR | X4 Pharmaceuticals, Inc | Baldry Mark | Chief Commercial Officer | P - Purchase | $2.48 | +1,032 | 25,337 | +4% | +$2,561 | ||||||
2025-05-16 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.55 | -29,552 | 1,682,258 | -2% | -$16,135 | ||||||
2025-05-19 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale | $126.25 | -3,806 | 5,427 | -41% | -$480,508 | ||||||
2025-05-19 | ABP | Abpro Holdings, Inc. | Suk Jin Wook (Miles) | CEO, COB | P - Purchase | $0.26 | +16,200 | 146,477 | +12% | +$4,212 | ||||||
2025-05-16 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $8.89 | -1,929 | 277,396 | -1% | -$17,149 | ||||||
2025-05-19 | VXRT | Vaxart, Inc. | Lo Steven | Pres, Chief Exec Officer | P - Purchase | $0.49 | +100,000 | 100,000 | New | +$49,000 | ||||||
| M | 2025-05-16 | FENC | Fennec Pharmaceuticals Inc. | Hackman Jeffrey S. | CEO | P - Purchase | $6.97 | +15,000 | 15,000 | New | +$104,602 | |||||
2025-05-16 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $6.78 | -16,667 | 70,254 | -19% | -$113,002 | ||||||
| A | 2025-05-14 | TARA | Protara Therapeutics, Inc. | Levy Richard S | Dir | P - Purchase | $3.19 | +20,000 | 51,000 | +65% | +$63,800 | |||||
| D | 2025-05-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $19.45 | -21,000 | 3,774,233 | -1% | -$408,450 | |||||
| D | 2025-05-16 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale+OE | $45.99 | -20,634 | 169,020 | -11% | -$948,958 | |||||
| D | 2025-05-16 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale+OE | $46.00 | -100,000 | 970,565 | -9% | -$4,600,000 | |||||
| D | 2025-05-15 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale+OE | $44.35 | -36,508 | 1,279,416 | -3% | -$1,619,130 | |||||
2025-05-15 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $46.18 | -25,000 | 694,395 | -3% | -$1,154,500 | ||||||
| DM | 2025-05-14 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale+OE | $47.58 | -136,383 | 480,646 | -22% | -$6,488,503 | |||||
| D | 2025-05-16 | EXEL | Exelixis, Inc. | Peterson Amy C. | EVP Prod Dev, Med Aff, CMO | S - Sale+OE | $45.47 | -72,776 | 465,393 | -14% | -$3,309,125 | |||||
2025-05-16 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.44 | -1,390 | 98,300 | -1% | -$615 | ||||||
2025-05-16 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.44 | -2,937 | 171,856 | -2% | -$1,300 | ||||||
2025-05-16 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.44 | -3,189 | 317,325 | -1% | -$1,412 | ||||||
| M | 2025-05-14 | ITOS | Iteos Therapeutics, Inc. | Ecor1 Capital, LLC | 10% | P - Purchase | $7.80 | +4,958,978 | 10,688,978 | +87% | +$38,685,562 | |||||
| M | 2025-05-14 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.57 | +400 | 139,366 | 0% | +$1,028 | |||||
2025-05-15 | ADVM | Adverum Biotechnologies, Inc. | Soparkar Peter | COO | S - Sale | $2.00 | -2,960 | 39,154 | -7% | -$5,920 | ||||||
2025-05-15 | ADVM | Adverum Biotechnologies, Inc. | Seyedkazemi Setareh | Chief Development Officer | S - Sale | $2.00 | -924 | 13,768 | -6% | -$1,848 | ||||||
2025-05-15 | ADVM | Adverum Biotechnologies, Inc. | Fischer Laurent | CEO, Pres, Dir | S - Sale | $2.00 | -9,126 | 87,488 | -9% | -$18,252 | ||||||
2025-05-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $99.82 | -2,500 | 165,674 | -1% | -$249,550 | ||||||
2025-05-14 | CRGX | Cargo Therapeutics, Inc. | Radhakrishnan Anup | See Remarks | S - Sale | $3.84 | -27,404 | 122,413 | -18% | -$105,272 | ||||||
| DM | 2025-05-14 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $41.89 | -28,125 | 260,354 | -10% | -$1,178,156 | |||||
2025-05-14 | IOVA | Iovance Biotherapeutics, Inc. | Vogt Frederick G | Interim CEO, GC | P - Purchase | $1.69 | +25,000 | 374,646 | +7% | +$42,250 | ||||||
2025-05-14 | TARA | Protara Therapeutics, Inc. | Levy Richard S | Dir | P - Purchase | $3.19 | +20,000 | 51,000 | +65% | +$63,800 | ||||||
2025-05-15 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale | $123.71 | -26,447 | 109,854 | -19% | -$3,271,688 | ||||||
2025-05-13 | ITOS | Iteos Therapeutics, Inc. | Gadicke Ansbert | Former 10% Owner | S - Sale | $8.06 | -1,031,931 | 3,452,797 | -23% | -$8,317,364 | ||||||
2025-05-13 | ITOS | Iteos Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | Former 10% Owner | S - Sale | $8.06 | -630,191 | 2,108,594 | -23% | -$5,079,339 | ||||||
2025-05-13 | ITOS | Iteos Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | Former 10% Owner | S - Sale | $8.06 | -630,191 | 2,108,594 | -23% | -$5,079,339 | ||||||
| D | 2025-05-12 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Dir | S - Sale+OE | $7.91 | -20,602 | 475,103 | -4% | -$163,046 | |||||
| M | 2025-05-08 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.70 | +9,500 | 391,107 | +2% | +$25,686 | |||||
2025-05-08 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $32.31 | -20,000 | 242,660 | -8% | -$646,260 | ||||||
2025-05-07 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $35.75 | -2,725 | 244,448 | -1% | -$97,419 | ||||||
| D | 2025-05-07 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $39.98 | -7,000 | 15,100 | -32% | -$279,860 | |||||
2025-05-07 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.72 | -5,000 | 105,849 | -5% | -$163,590 | ||||||
2025-05-08 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.81 | +5,000 | 381,607 | +1% | +$14,050 | ||||||
| M | 2025-05-05 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.96 | +46,959 | 376,607 | +14% | +$138,819 | |||||
| D | 2025-05-05 | NBIX | Neurocrine Biosciences Inc | Rastetter William H | Dir | S - Sale+OE | $110.20 | -30,000 | 37,491 | -44% | -$3,305,952 | |||||
2025-05-05 | IPSC | Century Therapeutics, Inc. | Farid Adrienne | Chief Operations Officer | S - Sale | $0.55 | -1,024 | 250,693 | 0% | -$563 | ||||||
2025-05-05 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.55 | -295 | 410,886 | 0% | -$162 | ||||||
2025-05-05 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $37.65 | -689 | 110,849 | -1% | -$25,942 | ||||||
2025-05-05 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $37.65 | -2,800 | 262,660 | -1% | -$105,423 | ||||||
2025-05-05 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $37.65 | -162 | 51,272 | 0% | -$6,099 | ||||||
2025-05-05 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $37.65 | -1,101 | 129,380 | -1% | -$41,454 | ||||||
| D | 2025-05-05 | NKGN | Nkgen Biotech, Inc. | Song Paul Y. | CEO | P - Purchase | $0.13 | +20,849,725 | 21,020,846 | >999% | +$2,650,000 | |||||
| D | 2025-05-05 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $37.65 | -5,042 | 655,432 | -1% | -$189,836 | |||||
2025-05-02 | AMGN | Amgen Inc | Busch Matthew C. | VP, Finance, CAO | S - Sale | $279.69 | -1,000 | 4,034 | -20% | -$279,690 | ||||||
2025-05-01 | EXEL | Exelixis, Inc. | Aftab Dana | CSO, EVP Disc, Trans Research | S - Sale | $39.00 | -1,508 | 699,016 | 0% | -$58,812 | ||||||
2025-05-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $6.31 | -10,000 | 53,587 | -16% | -$63,100 | ||||||
| D | 2025-05-01 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale+OE | $7.35 | -68,412 | 1,279,524 | -5% | -$502,828 | |||||
2025-05-02 | BIIB | Biogen Inc. | Dorsa Caroline | Dir | P - Purchase | $122.72 | +1,235 | 27,842 | +5% | +$151,559 | ||||||
| M | 2025-04-30 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.03 | +3,349 | 329,648 | +1% | +$6,793 | |||||
2025-04-29 | ABP | Abpro Holdings, Inc. | Suk Jin Wook (Miles) | CEO, COB | P - Purchase | $0.25 | +4,325 | 130,277 | +3% | +$1,081 | ||||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $3.02 | -12,103 | 390,081 | -3% | -$36,541 | |||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $3.07 | -19,191 | 355,376 | -5% | -$58,849 | |||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $3.02 | -31,562 | 583,490 | -5% | -$95,381 | |||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $3.02 | -14,587 | 391,385 | -4% | -$44,040 | |||||
2025-04-28 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.22 | +1,001 | 326,299 | 0% | +$2,222 | ||||||
| D | 2025-04-29 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $64.20 | -1,500 | 0 | -100% | -$96,300 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |